202 related articles for article (PubMed ID: 31285279)
1. Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer Cells.
Anantharajan J; Zhou H; Zhang L; Hotz T; Vincent MY; Blevins MA; Jansson AE; Kuan JWL; Ng EY; Yeo YK; Baburajendran N; Lin G; Hung AW; Joy J; Patnaik S; Marugan J; Rudra P; Ghosh D; Hill J; Keller TH; Zhao R; Ford HL; Kang C
Mol Cancer Ther; 2019 Sep; 18(9):1484-1496. PubMed ID: 31285279
[TBL] [Abstract][Full Text] [Related]
2. Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migration.
Krueger AB; Drasin DJ; Lea WA; Patrick AN; Patnaik S; Backos DS; Matheson CJ; Hu X; Barnaeva E; Holliday MJ; Blevins MA; Robin TP; Eisenmesser EZ; Ferrer M; Simeonov A; Southall N; Reigan P; Marugan J; Ford HL; Zhao R
J Biol Chem; 2014 Jun; 289(23):16349-61. PubMed ID: 24755226
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship studies of allosteric inhibitors of EYA2 tyrosine phosphatase.
Anantharajan J; Baburajendran N; Lin G; Loh YY; Xu W; Ahmad NHB; Liu S; Jansson AE; Kuan JWL; Ng EY; Yeo YK; Hung AW; Joy J; Hill J; Ford HL; Zhao R; Keller TH; Kang C
Protein Sci; 2022 Feb; 31(2):422-431. PubMed ID: 34761455
[TBL] [Abstract][Full Text] [Related]
4. Identification of a selective small-molecule inhibitor series targeting the eyes absent 2 (Eya2) phosphatase activity.
Krueger AB; Dehdashti SJ; Southall N; Marugan JJ; Ferrer M; Li X; Ford HL; Zheng W; Zhao R
J Biomol Screen; 2013 Jan; 18(1):85-96. PubMed ID: 22820394
[TBL] [Abstract][Full Text] [Related]
5. The EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone.
Tadjuidje E; Wang TS; Pandey RN; Sumanas S; Lang RA; Hegde RS
PLoS One; 2012; 7(4):e34806. PubMed ID: 22545090
[TBL] [Abstract][Full Text] [Related]
6. The EGFR/miR-338-3p/EYA2 axis controls breast tumor growth and lung metastasis.
Liang Y; Xu X; Wang T; Li Y; You W; Fu J; Liu Y; Jin S; Ji Q; Zhao W; Song Q; Li L; Hong T; Huang J; Lyu Z; Ye Q
Cell Death Dis; 2017 Jul; 8(7):e2928. PubMed ID: 28703807
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of ED-Eya2: insight into dual roles as a protein tyrosine phosphatase and a transcription factor.
Jung SK; Jeong DG; Chung SJ; Kim JH; Park BC; Tonks NK; Ryu SE; Kim SJ
FASEB J; 2010 Feb; 24(2):560-9. PubMed ID: 19858093
[TBL] [Abstract][Full Text] [Related]
8. Structure-based de novo design of Eya2 phosphatase inhibitors.
Park H; Ryu SE; Kim SJ
J Mol Graph Model; 2012 Sep; 38():382-8. PubMed ID: 23085179
[TBL] [Abstract][Full Text] [Related]
9. Aberrant hypomethylation and overexpression of the eyes absent homologue 2 suppresses tumor cell growth of human lung adenocarcinoma cells.
Gao T; Zheng S; Li Q; Ran P; Sun L; Yuan Y; Xiao C
Oncol Rep; 2015 Nov; 34(5):2333-42. PubMed ID: 26329363
[TBL] [Abstract][Full Text] [Related]
10. Structure-based virtual screening approach to the discovery of novel inhibitors of eyes absent 2 phosphatase with various metal chelating moieties.
Park H; Jung SK; Yu KR; Kim JH; Kim YS; Ko JH; Park BC; Kim SJ
Chem Biol Drug Des; 2011 Oct; 78(4):642-50. PubMed ID: 21777393
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic silencing of EYA2 in pancreatic adenocarcinomas promotes tumor growth.
Vincent A; Hong SM; Hu C; Omura N; Young A; Kim H; Yu J; Knight S; Ayars M; Griffith M; Van Seuningen I; Maitra A; Goggins M
Oncotarget; 2014 May; 5(9):2575-87. PubMed ID: 24810906
[TBL] [Abstract][Full Text] [Related]
12. Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis.
Zhou H; Blevins MA; Hsu JY; Kong D; Galbraith MD; Goodspeed A; Culp-Hill R; Oliphant MUJ; Ramirez D; Zhang L; Trinidad-Pineiro J; Mathews Griner L; King R; Barnaeva E; Hu X; Southall NT; Ferrer M; Gustafson DL; Regan DP; D'Alessandro A; Costello JC; Patnaik S; Marugan J; Zhao R; Ford HL
Cancer Res; 2020 Jun; 80(12):2689-2702. PubMed ID: 32341035
[TBL] [Abstract][Full Text] [Related]
13. Eya2 is critical for the E2A‑HLF‑mediated immortalization of mouse hematopoietic stem/progenitor cells.
Maharjan BD; Ono R; Nosaka T
Int J Oncol; 2019 Mar; 54(3):981-990. PubMed ID: 30628662
[TBL] [Abstract][Full Text] [Related]
14. Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-β signaling, epithelial-mesenchymal transition, and cancer stem cell properties.
Farabaugh SM; Micalizzi DS; Jedlicka P; Zhao R; Ford HL
Oncogene; 2012 Feb; 31(5):552-62. PubMed ID: 21706047
[TBL] [Abstract][Full Text] [Related]
15. Targeting EYA2 tyrosine phosphatase activity in glioblastoma stem cells induces mitotic catastrophe.
Zhang G; Dong Z; Gimple RC; Wolin A; Wu Q; Qiu Z; Wood LM; Shen JZ; Jiang L; Zhao L; Lv D; Prager BC; Kim LJY; Wang X; Zhang L; Anderson RL; Moore JK; Bao S; Keller TH; Lin G; Kang C; Hamerlik P; Zhao R; Ford HL; Rich JN
J Exp Med; 2021 Nov; 218(11):. PubMed ID: 34617969
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of miR-30a in lung adenocarcinoma A549 cell line inhibits migration and invasion via targeting EYA2.
Yuan Y; Zheng S; Li Q; Xiang X; Gao T; Ran P; Sun L; Huang Q; Xie F; Du J; Xiao C
Acta Biochim Biophys Sin (Shanghai); 2016 Mar; 48(3):220-8. PubMed ID: 26837415
[TBL] [Abstract][Full Text] [Related]
17. Dephosphorylation of the C-terminal tyrosyl residue of the DNA damage-related histone H2A.X is mediated by the protein phosphatase eyes absent.
Krishnan N; Jeong DG; Jung SK; Ryu SE; Xiao A; Allis CD; Kim SJ; Tonks NK
J Biol Chem; 2009 Jun; 284(24):16066-16070. PubMed ID: 19351884
[TBL] [Abstract][Full Text] [Related]
18. Rational design of novel allosteric EYA2 inhibitors as potential therapeutics for multiple brain cancers.
Gardner L; Rossi J; Armstrong B; Muse M; LaVeck A; Blevins M; Zhang L; Ford H; Zhao R; Wang X
ChemMedChem; 2024 Jun; ():e202400179. PubMed ID: 38861151
[TBL] [Abstract][Full Text] [Related]
19. EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression.
Wolin AR; Vincent MY; Hotz T; Purdy SC; Rosenbaum SR; Hughes CJ; Hsu JY; Oliphant MUJ; Armstrong B; Wessells V; Varella-Garcia M; Galbraith MD; Pierce A; Wang D; Venkataraman S; Danis E; Veo B; Serkova N; Espinosa JM; Gustafson DL; Vibhakar R; Ford HL
Neuro Oncol; 2023 Dec; 25(12):2287-2301. PubMed ID: 37486991
[TBL] [Abstract][Full Text] [Related]
20. miR-30a suppresses breast cancer cell proliferation and migration by targeting Eya2.
Fu J; Xu X; Kang L; Zhou L; Wang S; Lu J; Cheng L; Fan Z; Yuan B; Tian P; Zheng X; Yu C; Ye Q; Lv Z
Biochem Biophys Res Commun; 2014 Mar; 445(2):314-9. PubMed ID: 24508260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
